GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prestige Biologics Co Ltd (XKRX:334970) » Definitions » ROIC %

Prestige Biologics Co (XKRX:334970) ROIC % : -10.94% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Prestige Biologics Co ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Prestige Biologics Co's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -10.94%.

As of today (2024-12-15), Prestige Biologics Co's WACC % is 8.33%. Prestige Biologics Co's ROIC % is -10.64% (calculated using TTM income statement data). Prestige Biologics Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Prestige Biologics Co ROIC % Historical Data

The historical data trend for Prestige Biologics Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Biologics Co ROIC % Chart

Prestige Biologics Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Jun23 Jun24
ROIC %
Get a 7-Day Free Trial Premium Member Only -30.11 -21.71 -18.06 -7.87 -10.57

Prestige Biologics Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.63 -14.55 -15.21 -2.36 -10.94

Competitive Comparison of Prestige Biologics Co's ROIC %

For the Biotechnology subindustry, Prestige Biologics Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Biologics Co's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prestige Biologics Co's ROIC % distribution charts can be found below:

* The bar in red indicates where Prestige Biologics Co's ROIC % falls into.



Prestige Biologics Co ROIC % Calculation

Prestige Biologics Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jun. 2024 is calculated as:

ROIC % (A: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2023 ) + Invested Capital (A: Jun. 2024 ))/ count )
=-33429.985 * ( 1 - 0% )/( (317015.569 + 315348.4)/ 2 )
=-33429.985/316181.9845
=-10.57 %

where

Invested Capital(A: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=305753.043 - 7592.946 - ( 45434.774 - max(0, 89097.644 - 70242.172+45434.774))
=317015.569

Invested Capital(A: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=289414.061 - 10735.928 - ( 29507.247 - max(0, 92305.793 - 55635.526+29507.247))
=315348.4

Prestige Biologics Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-37224.512 * ( 1 - 0% )/( (315348.4 + 365066.546)/ 2 )
=-37224.512/340207.473
=-10.94 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=289414.061 - 10735.928 - ( 29507.247 - max(0, 92305.793 - 55635.526+29507.247))
=315348.4

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=335337.56 - 7868.076 - ( 36560.469 - max(0, 127162.4 - 89565.338+36560.469))
=365066.546

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prestige Biologics Co  (XKRX:334970) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Prestige Biologics Co's WACC % is 8.33%. Prestige Biologics Co's ROIC % is -10.64% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Prestige Biologics Co ROIC % Related Terms

Thank you for viewing the detailed overview of Prestige Biologics Co's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Biologics Co Business Description

Traded in Other Exchanges
N/A
Address
197, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Chungcheongbuk-do, Cheongju-si, KOR, 28161
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).

Prestige Biologics Co Headlines

No Headlines